Best Practices for Drawing and Delivering Bevacizumab for Retinopathy of Prematurity

PLEASE NOTE: Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP).

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org.

3 posts / 0 new

Last post

Thu, 07/04/2024 - 19:39

Harriet Kusi

Offline

Last seen: 1 week 1 day ago

Joined: 05/08/2024 - 19:41

Best Practices for Drawing and Delivering Bevacizumab for Retinopathy of Prematurity

Hi everyone,

How do your sites draw up and deliver bevacizumab for intravitreal administration for retinopathy of prematurity? We have a NICU protocol with a dose of 0.05 mL of bevacizumab drawn up in a 1 mL syringe and delivered to the unit. The dose to be administered is 0.025 mL. However, since this dose is very small, our pharmacy dispenses 0.05 mL for the proceduralist to administer half of the dispensed dose. There are potential errors associated with this practice, and we are evaluating our workflow.

Wanted to hear how other pediatric centers dispense these types of doses.

Thanks,
Harriet

Members Log In